What Daflon Treats: Main Uses and Benefits

Daflon is considered relevant for easing symptoms related to venolymphatic insufficiency and acute hemorrhoidal episodes. Its core therapeutic use is to provide supportive relief in clinical settings marked by increased discomfort or tension. The medication is applied across domains where additional symptomatic support is needed.

---

Symptomatic Relief for Chronic Venous Issues

This helps address symptom clusters related to chronic venous circulation disorders in the legs, such as heavy legs, pain, leg cramps, and restless legs. Daflon plays a role in managing symptoms that interfere with daily comfort and contributes to improved day-to-day comfort during symptomatic periods. Relevant when symptoms become more noticeable: “The medication offers symptomatic relief that helps patients cope more steadily.”

Management of Acute Episodes

Daflon is applied across conditions presenting with acute episodes. It is used in settings where symptoms become temporarily overwhelming, helping to address the sudden and intense symptom cluster of pain, swelling, and bleeding associated with this condition, and assists with maintaining functional stability.

---

Quick Fact: Relief for Heavy Legs
Provides supportive relief when heavy legs and related symptoms interfere with daily functioning.

Regulatory References

1. Philippines FDA Drug Verification Portal

Who can and cannot use Daflon? (Eligibility and Restrictions)

The population eligibility for Daflon is strictly defined by government regulatory documents, focusing on age, physiological status, and known allergies. Use is generally intended for adults who are seeking symptomatic relief for conditions like chronic venous insufficiency.

---

Official Eligibility Rules

Category	Eligibility Status (Regulatory)
Absolute Contraindication	Patients with known hypersensitivity (allergy) to the active substance, Micronized Purified Flavonoid Fraction (MPFF), or any other tablet ingredients.
Children and Adolescents	Not recommended for those under 18 years of age because safety and efficacy have not been established in this population.
Pregnancy	Preferable to avoid use as a precautionary measure due to the limited availability of clinical data on its use in pregnant women.
Breastfeeding	Not recommended as it is unknown if the active substances are excreted in human milk, and a risk to the infant cannot be excluded.
Organ Impairment	Use with caution in patients with severe hepatic (liver) or renal (kidney) impairment, as specific dose adjustment studies have not been performed.

Interactions with other medicines and products

The official regulatory profile for Daflon (Micronized Purified Flavonoid Fraction) is defined by the documented absence of both formal interaction study data and clinically significant reports from post-marketing surveillance. This information is consistently stated across authoritative government-approved prescribing documents.

Interaction Scope

Category
Medicinal product categories with documented interactions: None documented.
Specific interacting medicines (if explicitly listed): None listed.
Mechanistic basis of interactions: No formal interaction studies have been performed to identify pharmacokinetic mechanisms such as enzyme (CYP) or transporter-mediated effects.
Timing-based interaction rules: None documented. No mandatory time separation is required for co-administration.
Population-specific interaction notes: None documented regarding interaction significance in specific populations (e.g., in hepatic impairment).
Interaction-related restrictions: No formal restrictions or prohibitions are documented regarding co-administration with other medicinal products.

Resulting Interaction Structure

Official Interaction Statements:

• No interaction studies have been performed, as stated in the regulatory documentation.
• No clinically relevant drug interaction has been reported to date from post-marketing experience on the product.

Connection to the overall interaction profile:

The regulatory documents define the product's interaction structure by stating the absence of both formal study data and clinically significant post-marketing reports. The official labeling confirms that no pharmacokinetic, pharmacodynamic, or administration-timing constraints related to interactions are currently required. This means no special precautions or timing separation requirements are needed based on documented interaction reports.

Daflon, a micronized purified flavonoid fraction (MPFF), modulates the vascular system through multiple mechanisms, primarily targeting the venous wall and microcirculation. At the level of the venous and venular smooth muscle, the active constituent, diosmin, potentiates the noradrenergic contractile response by prolonging the activity of parietal norepinephrine. This interaction leads to an increase in venous parietal tone, reducing venous capacitance and distensibility.

In the microcirculation, MPFF exerts anti-inflammatory and vasculoprotective actions. It directly influences the endothelium, leading to a downregulation of the expression of endothelial adhesion molecules, specifically ICAM-1 (Intercellular Adhesion Molecule-1) and VCAM-1 (Vascular Cell Adhesion Molecule-1). This molecular action consequently inhibits the activation, adhesion, and trans-endothelial migration of leukocytes. The inhibition of leukocyte-endothelium interaction decreases the subsequent release of inflammatory mediators and reactive oxygen species (free radicals). This cascade leads to the normalization of capillary hyperpermeability and reinforcement of capillary resistance.

The use of Daflon (Micronized Purified Flavonoid Fraction) follows a standardized dosing and administration protocol. The medication is delivered exclusively via the oral route as a film-coated tablet, available in 500 mg and 1000 mg strengths. Instructions specify that tablets be taken at meal times to ensure proper intake.

The required daily dose is determined by the specific use case, following two distinct labeled regimens:

Regimen	Total Daily Dose	Frequency and Duration Pattern
Chronic Venous Support	1000 mg	Usually taken in two divided doses daily (e.g., 500 mg twice daily) or once daily (with the 1000 mg tablet).
Acute Intensive Course	Days 1–4: 3000 mg; Days 5–7: 2000 mg	A fixed, short-term, seven-day reduction sequence administered in divided doses throughout the day.

For the 1000 mg tablet strength, the score line on the tablet is solely to facilitate ease of swallowing and is not intended for dividing the dose. In the event of a missed dose, the next dose should be taken at the usual time, and a double dose must not be taken to compensate. Safety and efficacy for individuals under 18 years of age have not been established in the product information.

Research Evidence / Overview of Studies for Daflon

Research Evidence for Symptoms of Chronic Venous Disease (CVD)

This section will summarize the available high-quality research, primarily Randomized Controlled Trials (RCTs) and meta-analyses, that have examined the effect of the medicine on patient-reported outcomes like heavy legs, pain, and feeling of swelling, as well as objective measures of leg edema (swelling).

The evidence base for the use of Micronized Purified Flavonoid Fraction (MPFF) in symptomatic Chronic Venous Disease involves RCTs and observational studies, including numerous double-blind, placebo-controlled trials and comprehensive systematic reviews. Research has examined patient-reported outcomes describing perceived discomfort, such as the severity of leg pain and the subjective feeling of swelling. Studies monitored how these symptoms evolved in the observed populations. The findings describe patterns observed in the studies where patients reported changes in severity scores for these core symptoms, and reports of functional discomfort were evaluated using specific scales. Additionally, some trials monitored objective measures like changes in ankle circumference, which was studied as a proxy measure for leg edema.

Research Evidence for Managing Acute Hemorrhoidal Episodes

This part will focus on the research base, mainly short-term RCTs, that has investigated the use of the medicine for the management of acute symptoms of episodes, specifically looking at outcomes related to bleeding, pain, and discomfort.

Studies monitored key outcomes related to physical discomfort, including bleeding, pain, and pruritus (itching), during periods of heightened symptom activity. Findings from the research describe patterns measured during the study period where changes in the severity scores for acute symptoms, particularly bleeding and pain, were observed over a shorter duration. Research also explored short-term symptom changes following surgical procedures, where the medicine was evaluated as an adjunctive treatment in studies examining outcomes related to postoperative pain.

Research Evidence for Venous Leg Ulcer Healing (Adjunctive Use)

This segment will review the clinical trials and systematic reviews that have explored the use of the medicine as an add-on treatment to standard compression therapy for the management of venous leg ulcers, focusing on measured outcomes like ulcer healing rates and time to complete healing.

Systematic reviews consolidating the evidence have described a pattern where a larger proportion of patients whose ulcers healed was observed when the medicine was added to standard compression therapy. However, the certainty of this finding remains low or moderate, as the results of the most rigorously conducted individual trials did not always describe a substantial additional change in healing rates. This finding indicates that evidence quality varies across studies and that the overall conclusion needs to be interpreted cautiously.

Documented Research Gaps and Uncertainties

While the evidence base is extensive for symptom evaluation in the short term, one major limitation is that long-term effects are not fully established and there is limited information on outcomes that reflect long-term disease progression. Follow-up durations in most high-quality trials were limited, typically lasting only a few months. Furthermore, data for certain groups remain insufficient, and comparative evidence against all other non-pharmacological and pharmacological treatment options remains limited in some areas. Research provides context but not individual predictions.

Key Studies & References

1. Venoactive medications and the place of MPFF at a dose of 500 mg in recent guidelines on the management of chronic venous disease
2. DAFLON 500 mg, film-coated tablets (Summary of Product Characteristics/Regulatory Data)

Common questions about Daflon (FAQ)

Q: Is Daflon generally considered appropriate for long-term use for chronic vein conditions?

A: Evidence has described that the medication is well-tolerated when used continuously for extended periods. Clinical studies have examined the safety profile for use of at least 12 months of continuous administration. The decision on the appropriate duration of treatment for chronic conditions should be made in consultation with a healthcare professional.

Q: What is the functional difference between Daflon 500 mg and Daflon 1000 mg?

A: The 1000, mg tablet contains twice the active ingredients compared to the 500, mg tablet. A key difference is convenience, as the 1000, mg strength is formulated to allow the standard daily dose for venous disease to be taken in a single tablet.

Q: Is it normal to experience a feeling of lightness in the legs after using Daflon for a while?

A: Official documentation states the medication is indicated for relieving symptoms of venolymphatic insufficiency, including the sensation of heavy legs. Studies report that relief of this symptom occurs, which may be perceived as a feeling of lightness.

Q: How long does it typically take to notice the effects of Daflon on symptoms like heavy legs?

A: Clinical data suggests that perceived relief of symptoms often begins within the first two months of treatment. Significant improvement has been reported within the first month of continuous use.

Q: What is the typically recommended length of time to use Daflon for chronic venous issues?

A: The appropriate duration of treatment for chronic venous conditions should be determined by a healthcare professional. Clinical data supports continuous use for periods of up to 12 months, but extended use is typically overseen by a healthcare professional.

Q: Is it necessary to avoid alcohol completely while taking Daflon?

A: There is no specific drug interaction documented with alcohol in the product information. However, alcohol consumption is generally noted as potentially worsening the symptoms of underlying venous conditions or hemorrhoids.

Q: Do I need to make changes to my diet, like increasing fiber, while taking Daflon for hemorrhoids?

A: Official guidance suggests that for hemorrhoidal episodes, the treatment is typically intended to be used alongside a healthy lifestyle. This lifestyle guidance includes the suggestion of a diet rich in fiber to help prevent constipation.

Q: Is Daflon considered a blood thinner, similar to aspirin or warfarin?

A: No, according to its pharmacological classification, the medication is defined as a vasculoprotector and phlebotonic agent. This means it works to support the integrity and tone of blood vessel walls, and it is not classified as an anticoagulant or antiplatelet drug (a blood thinner).

Q: Are there any restrictions on physical activities like running or cycling while taking Daflon?

A: No specific restrictions on physical activity are documented in the product information. Measures like walking are noted as beneficial to promote blood circulation while managing venous conditions.

Q: Does Daflon have an effect on blood pressure levels?

A: Clinical safety studies, including those that examined the effects of prolonged treatment for up to one year, found that the medication did not significantly influence blood pressure. Standard hemodynamic parameters were reported as uninfluenced.

Q: What should I do if my symptoms do not improve after the standard treatment period?

A: Regulatory guidance provides specific instructions for the treatment of acute hemorrhoidal symptoms. If the condition persists for more than 15 days, official guidance notes that a consultation with a healthcare professional is appropriate.

Q: Are there specific complementary lifestyle changes, like wearing compression stockings, that should be used alongside Daflon?

A: Official patient information notes that for venous circulation disorders, the treatment is used alongside a healthy lifestyle. This includes measures such as wearing special support stockings and walking to stimulate blood circulation.

Q: Is there any evidence that Daflon could affect hormones or menstrual cycles?

A: The adverse events reported in clinical trials and post-marketing experience do not list any effects on hormones or the menstrual cycle among the known or suspected side effects.

Q: What is the reported rate of people stopping Daflon treatment due to side effects?

A: Clinical trial data indicates that side effects are primarily mild. The rate of participants who discontinued treatment due to adverse events was reported as 1.1% in relevant studies.

Q: Does Daflon require any specific monitoring of blood tests while taking it?

A: Clinical safety data, including from studies on prolonged use, found that the medication did not influence standard laboratory values for hematology, liver function, or kidney function tests. Routine blood monitoring is not specified in the labeling.

How to Store and Dispose of Daflon?

Storage Requirements

Official regulatory documents require that Daflon tablets be stored below 30 C to maintain product stability. The medicine must be kept in the original container or outer packaging, and it must not be used after the expiry date printed on the carton. For safety, the product must always be stored out of the sight and reach of children.

Disposal Instructions

The disposal of unused or expired Daflon must follow specific environmental rules. The labeling strictly states that the medicine should not be thrown away via wastewater or household waste. The official instruction is to ask a pharmacist how to dispose of medicines no longer required. These regulated steps help ensure environmental protection.